Ionis Pharmaceuticals, Inc. (IONS)
62.03
+2.29
(+3.83%)
USD |
NASDAQ |
Aug 24, 16:00
61.98
-0.05
(-0.08%)
After-Hours: 20:00
Ionis Pharmaceuticals Gross Profit Margin (Quarterly) : 96.13% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 96.13% |
| March 31, 2026 | 95.76% |
| December 31, 2025 | 94.14% |
| September 30, 2025 | 96.67% |
| June 30, 2025 | 98.45% |
| March 31, 2025 | 94.79% |
| December 31, 2024 | 95.92% |
| September 30, 2024 | 95.09% |
| June 30, 2024 | 95.67% |
| March 31, 2024 | 93.47% |
| December 31, 2023 | 97.35% |
| September 30, 2023 | 94.60% |
| June 30, 2023 | 95.63% |
| March 31, 2023 | 94.68% |
| December 31, 2022 | 92.74% |
| September 30, 2022 | 95.86% |
| June 30, 2022 | 92.65% |
| March 31, 2022 | 93.61% |
| December 31, 2021 | 98.41% |
| September 30, 2021 | 94.15% |
| June 30, 2021 | 93.66% |
| March 31, 2021 | 93.34% |
| December 31, 2020 | 97.39% |
| September 30, 2020 | 95.29% |
| June 30, 2020 | 95.16% |
| Date | Value |
|---|---|
| March 31, 2020 | 95.01% |
| December 31, 2019 | 98.97% |
| September 30, 2019 | 97.23% |
| June 30, 2019 | 96.93% |
| March 31, 2019 | 98.46% |
| December 31, 2018 | 97.76% |
| September 30, 2018 | 0.00% |
| June 30, 2018 | 0.00% |
| March 31, 2018 | 0.00% |
| December 31, 2017 | |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| December 31, 2015 | 0.00% |
| September 30, 2015 | 0.00% |
| June 30, 2015 | 0.00% |
| March 31, 2015 | 0.00% |
| December 31, 2014 | 0.00% |
| September 30, 2014 | 0.00% |
| June 30, 2014 | 0.00% |
| March 31, 2014 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Biogen, Inc. | 61.37% |
| BridgeBio Pharma, Inc. | 93.68% |
| Vertex Pharmaceuticals, Inc. | 85.37% |
| Arrowhead Pharmaceuticals, Inc. | 91.15% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -105.8% |
| Return on Assets | -17.66% |
| Return on Invested Capital | -20.02% |
| Profit Margin (Quarterly) | -42.79% |
| Operating Margin (Quarterly) | -38.18% |
| Return on Net Operating Assets | -133.8% |